logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Marc Buyse

international drug development institute
H指数:101
被引数:4.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers

BRCA1致病性变异携带者三阴性乳腺癌的个体化孕激素受体调节剂预防策略

npj Breast Cancer
IF7.6
2026-06-250
OA
Martin Widschwendter; Rita Schmutzler; Nora Pashayan; Jelle Wesseling; Marc Tischkowitz; Michal Zikan; Miranda Steenbeek; Marike Gabrielson; Christian F. Singer; Cathrin Brisken; Rebecca Gomperts; Sharon Cameron; Dafydd Gareth Evans; Andri Papakonstantinou; Marc Buyse; Kerstin Rhiem; Mateja Krajc; Charlotte Vavourakis; Elisa Redl; Chiara Herzog; James Barrett; Mohammed Fatih Rasul; Deborah Utjés; Kiriaki Papaikonomou; Angelique Flöter Rådestad; Athanasios Zouzos; Twana Alkasalias; Kristina Gemzell-Danielsson
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy

评估化疗在膀胱癌辅助治疗中总体生存率的替代指标

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
IF2.3
2025-09-010
OAAI
Sternberg, C. N.; Squifflet, P.; Saad, E. D.; Burdett, S.; Fisher, D.; Kurt, M.; Teitsson, S.; May, J. R.; Patel, M. Y.; Stoeckle, M.; Torti, F.; Cote, R.; Ruggeri, E. M.; Zhegalik, A.; Tierney, J. F.; Collette, L.; Burzykowski, T.; Buyse, M.
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
CLINICAL COLORECTAL CANCER
IF3.2
2025-03-010
PRE
Assaf, Irene; Bregni, Giacomo; Anthoine, Geraldine; Aparicio, Thomas; Artru, Pascal; Ben Abdelghani, Meher; Buyse, Marc; Chibaudel, Benoist; Coart, Elisabeth; Diaz, Marie; Evrard, Camille; Geboes, Karen; Ghiringhelli, Francois; Puleo, Francesco; Raimbourg, Judith; Vandamme, Timon; van den Eynde, Marc; Hendlisz, Alain; Sclafani, Francesco
Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)
ANNALS OF ONCOLOGY
IF65.4
2024-06-010
PRE
Sclafani, F.; Bregni, G.; Assaf, I.; Puleo, F.; Vergauwe, P.; Prenen, H.; Diaz, M.; Gokburun, Y.; Sanchez, A. Veron; Anthoine, G.; Moretti, L.; Galdon, M. Gomez; Liberale, G.; Martinive, P.; Geboes, K.; Carrasco, J.; van den Eynde, M.; van Laethem, J-L.; Buyse, M. E.; Hendlisz, A.
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
BRITISH JOURNAL OF CANCER
IF6.8
2024-02-240
OA
Karapetis, C. S.; Liu, H.; Sorich, M. J.; Pederson, L. D.; Van Cutsem, E.; Maughan, T.; Douillard, J. Y.; O'Callaghan, C. J.; Jonker, D.; Bokemeyer, C.; Sobrero, A.; Cremolini, C.; Chibaudel, B.; Zalcberg, J.; Adams, R.; Buyse, M.; Peeters, M.; Yoshino, T.; de Gramont, A.; Shi, Q.
Assessing PSA
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
PRE
Halabi, S.; Roy, A.; Guo, S.; Rydzewska, L.; Godolphin, P. J.; Parmar, M. K.; Hussain, M.; Tangen, C.; Thompson, I. M.; Carducci, M. A.; Smith, M. R.; Morris, M. J.; Gravis, G.; Dearnaley, D.; Verhagen, P.; Goto, T.; James, N. D.; Buyse, M. E.; Tierney, J.; Sweeney, C.
Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
PRE
Ravi, P.; Xie, W.; Buyse, M. E.; Halabi, S.; Kantoff, P. W.; Sartor, O.; Attard, G.; Clarke, N. W.; D'Amico, A.; Dignam, J.; James, N. D.; Fizazi, K.; Gillessen, S.; Parulekar, W. R.; Sandler, H.; Spratt, D.; Sydes, M. R.; Tombal, B.; Williams, S.; Sweeney, C.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

以曲妥珠单抗为基础的HER2-positive乳腺癌辅助治疗后neratinib的总生存期 (ExteNET): 一项随机、双盲、安慰剂对照的3期试验

EUROPEAN JOURNAL OF CANCER
IF7.1
2023-05-0114
OAAI
Holmes, Frankie A.; Moy, Beverly; Delaloge, Suzette; Chia, Stephen K. L.; Ejlertsen, Bent; Mansi, Janine; Iwata, Hiroji; Gnant, Michael; Buyse, Marc; Barrios, Carlos H.; Silovski, Tajana; Separovic, Robert; Bashford, Anna; Zotano, Angel Guerrero; Denduluri, Neelima; Patt, Debra; Gokmen, Erhan; Gore, Ira; Ii, John W. Smith; Loibl, Sibylle; Masuda, Norikazu; Tomasevic, Zorica; Petrakova, Katarina; DiPrimeo, Daniel; Wong, Alvin; Martin, Miguel; Chan, Arlene

研究方向

暂未获取到该数据
E
Everardo D. Saad
H 指数:30论文数:157被引数:3,551
B
Burzykowski, Tomasz
H 指数:0论文数:0被引数:18
P
Pascal Piedbois
H 指数:39论文数:181被引数:5,837
D
Daniel J. Sargent
H 指数:109论文数:769被引数:8.7万
M
Martine Piccart
H 指数:149论文数:1,553被引数:11.5万
A
Aimery de Gramont
H 指数:78论文数:598被引数:3.6万
S
Stefan Michiels
H 指数:85论文数:1,028被引数:3.1万
E
Eric Van Cutsem
H 指数:174论文数:1,832被引数:17.5万
O
Oriana Ciani
H 指数:39论文数:264被引数:4,346
M
Miguel Martín
H 指数:107论文数:1,252被引数:4.7万